Tonix Pharmaceuticals Holding Corp Asset Resilience Ratio
Tonix Pharmaceuticals Holding Corp asset resilience ratio. Tonix Pharmaceuticals Holding Corp (TNXP) has an Asset Resilience Ratio of 0.62% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tonix Pharmaceuticals Holding Corp (TNXP) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tonix Pharmaceuticals Holding Corp (2012–2017)
Asset resilience ratio of Tonix Pharmaceuticals Holding Corp from 2012 to 2017. This chart shows how Tonix Pharmaceuticals Holding Corp's Asset Resilience Ratio has changed over time. Read how much debt does Tonix Pharmaceuticals Holding Corp carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tonix Pharmaceuticals Holding Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Tonix Pharmaceuticals Holding Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $99.00K | 0.62% |
| Total Liquid Assets | $99.00K | 0.62% |
Asset Resilience Insights
- Limited Liquidity: Tonix Pharmaceuticals Holding Corp maintains only 0.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tonix Pharmaceuticals Holding Corp Industry Peers by Asset Resilience Ratio
Compare Tonix Pharmaceuticals Holding Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Tonix Pharmaceuticals Holding Corp Asset Resilience Ratio by Year (2012–2017)
Tonix Pharmaceuticals Holding Corp asset resilience ratio by year from 2012 to 2017. The table below shows the annual Asset Resilience Ratio data for Tonix Pharmaceuticals Holding Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 26.84% | $7.18 Million | $26.75 Million | +0.74pp |
| 2016-12-31 | 26.10% | $7.18 Million | $27.51 Million | -24.61pp |
| 2015-12-31 | 50.71% | $23.84 Million | $47.02 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $39.54 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $8.74 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $2.12 Million | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more